This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Organic compounds are arguably the foundation of the pharmaceutical industry. All traditional small molecule pharmaceuticals include carbon building blocks” Organic compounds are arguably the foundation of the pharmaceutical industry. Org Process Res Dev 2020, 24, 10, 1996–2003.
The world’s biggest pharmaceuticalcompany Pfizer announced in June 2008 that it would be putting its “full scope and scale” behind a push into the cancer market. ” “Between 2003 and 2005 global sales for cancer-treating drugs grew by 40%.”
After the outbreak of any epidemic or pandemic, all the responsibilities come on the shoulders of pharmaceuticalcompanies. With unprecedented diseases lurking on the corner, pharmaceuticalcompanies, are now obligated to widen their conventional horizons and look for substitute practices in their drug development strategies.
In an era when the world is accelerating the development of drugs and targeted medicines using innovative technologies, pharmaceuticalcompanies still face registration hurdles for well-characterized molecules because of redundant or additional local regulatory requirements. Published February 2003. Published February 2003.
A few decades ago, gathering genetic data on the scale of the 100,000 Genomes Project would have been unthinkable – it was only in 2003 that the entire human genome was mapped. The power of AI is also being harnessed to sift through vast amounts of data to determine potential areas of treatment or to discover new uses for old compounds.
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content